Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Total Debt: 2010-2025

Historic Total Debt for OptimizeRx (OPRX) over the last 7 years, with Q3 2025 value amounting to $28.1 million.

  • OptimizeRx's Total Debt fell 2034.41% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 2034.41%. This contributed to the annual value of $32.8 million for FY2024, which is 942.56% down from last year.
  • As of Q3 2025, OptimizeRx's Total Debt stood at $28.1 million, which was down 2034.41% from $28.4 million recorded in Q2 2025.
  • In the past 5 years, OptimizeRx's Total Debt ranged from a high of $36.2 million in Q4 2023 and a low of $28.1 million during Q3 2025
  • Its 3-year average for Total Debt is $33.1 million, with a median of $34.0 million in 2024.
  • As far as peak fluctuations go, OptimizeRx's Total Debt tumbled by 942.56% in 2024, and later plummeted by 2034.41% in 2025.
  • Over the past 3 years, OptimizeRx's Total Debt (Quarter) stood at $36.2 million in 2023, then decreased by 9.43% to $32.8 million in 2024, then dropped by 14.37% to $28.1 million in 2025.
  • Its Total Debt stands at $28.1 million for Q3 2025, versus $28.4 million for Q2 2025 and $32.5 million for Q1 2025.